DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ku, Jayoung | ko |
dc.contributor.author | Kim, Ryul | ko |
dc.contributor.author | Kim, Dongchan | ko |
dc.contributor.author | Kim, Daeyoon | ko |
dc.contributor.author | Song, Seulki | ko |
dc.contributor.author | Lee, Keonyong | ko |
dc.contributor.author | Lee, Namseok | ko |
dc.contributor.author | Kim, MinA | ko |
dc.contributor.author | Yoon, Sung-Soo | ko |
dc.contributor.author | Kwon, Nam Hoon | ko |
dc.contributor.author | Kim, Sunghoon | ko |
dc.contributor.author | Kim, Yoosik | ko |
dc.contributor.author | Koh, Youngil | ko |
dc.date.accessioned | 2020-11-30T07:30:11Z | - |
dc.date.available | 2020-11-30T07:30:11Z | - |
dc.date.created | 2020-11-23 | - |
dc.date.created | 2020-11-23 | - |
dc.date.issued | 2020-10 | - |
dc.identifier.citation | COMMUNICATIONS BIOLOGY, v.3, no.1, pp.630 | - |
dc.identifier.issn | 2399-3642 | - |
dc.identifier.uri | http://hdl.handle.net/10203/277741 | - |
dc.description.abstract | Aminoacyl-tRNA synthetase-interacting multifunctional protein 2 (AIMP2) is a non-enzymatic component required for the multi-tRNA synthetase complex. While exon 2 skipping alternatively spliced variant of AIMP2 (AIMP2-DX2) compromises AIMP2 activity and is associated with carcinogenesis, its clinical potential awaits further validation. Here, we found that AIMP2-DX2/AIMP2 expression ratio is strongly correlated with major cancer signaling pathways and poor prognosis, particularly in acute myeloid leukemia (AML). Analysis of a clinical patient cohort revealed that AIMP2-DX2 positive AML patients show decreased overall survival and progression-free survival. We also developed targeted RNA-sequencing and single-molecule RNA-FISH tools to quantitatively analyze AIMP2-DX2/AIMP2 ratios at the single-cell level. By subclassifying hematologic cancer cells based on their AIMP2-DX2/AIMP2 ratios, we found that downregulating AIMP2-DX2 sensitizes cells to anticancer drugs only for a subgroup of cells while it has adverse effects on others. Collectively, our study establishes AIMP2-DX2 as a potential biomarker and a therapeutic target for hematologic cancer. Ku, Kim et al develop a method to analyse the ratio of the alternatively spliced variant of AIMP2 to full length AIMP via single-molecule RNA-FISH. They can subclassify hematologic cancer based on AIMP2-DX2/AIMP2 ratio and find that cells with high AIMP2-DX2 ratio can be sensitized to chemotherapy drugs by depleting AIMP2-DX2. | - |
dc.language | English | - |
dc.publisher | NATURE RESEARCH | - |
dc.title | Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer | - |
dc.type | Article | - |
dc.identifier.wosid | 000588120400005 | - |
dc.identifier.scopusid | 2-s2.0-85094675296 | - |
dc.type.rims | ART | - |
dc.citation.volume | 3 | - |
dc.citation.issue | 1 | - |
dc.citation.beginningpage | 630 | - |
dc.citation.publicationname | COMMUNICATIONS BIOLOGY | - |
dc.identifier.doi | 10.1038/s42003-020-01353-x | - |
dc.contributor.localauthor | Kim, Yoosik | - |
dc.contributor.nonIdAuthor | Kim, Ryul | - |
dc.contributor.nonIdAuthor | Kim, Dongchan | - |
dc.contributor.nonIdAuthor | Kim, Daeyoon | - |
dc.contributor.nonIdAuthor | Song, Seulki | - |
dc.contributor.nonIdAuthor | Lee, Keonyong | - |
dc.contributor.nonIdAuthor | Lee, Namseok | - |
dc.contributor.nonIdAuthor | Kim, MinA | - |
dc.contributor.nonIdAuthor | Yoon, Sung-Soo | - |
dc.contributor.nonIdAuthor | Kwon, Nam Hoon | - |
dc.contributor.nonIdAuthor | Kim, Sunghoon | - |
dc.contributor.nonIdAuthor | Koh, Youngil | - |
dc.description.isOpenAccess | Y | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | ACUTE MYELOID-LEUKEMIA | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | P53 | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | MUTATION | - |
dc.subject.keywordPlus | KINASE | - |
dc.subject.keywordPlus | TARGET | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.